PREMIER CONSULTING

Serial Number 97088470
Registration 7264370
700

Registration Progress

Application Filed
Oct 22, 2021
Under Examination
Approved for Publication
Published for Opposition
Registered
Jan 2, 2024

Trademark Image

PREMIER CONSULTING

Basic Information

Serial Number
97088470
Registration Number
7264370
Filing Date
October 22, 2021
Registration Date
January 2, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 2, 2024
Registration
Registered
Classes
042

Rights Holder

Premier Research International LLC

16
Address
3800 Paramount Parkway, Suite 400
Morrisville, NC 27560

Ownership History

Premier Research International LLC

Original Applicant
16
Morrisville, NC

Premier Research International LLC

Original Registrant
16
Morrisville, NC

Legal Representation

Attorney
ROBERT P. PARKER

USPTO Deadlines

Next Deadline
1475 days remaining
Section 8 Declaration Due (Supplemental Register) (Based on registration date 20240102)
Due Date
January 02, 2030
Grace Period Ends
July 02, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description Documents
Jan 2, 2024 NRCS E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 2, 2024 R.SR A REGISTERED-SUPPLEMENTAL REGISTER Loading...
May 9, 2023 EXPT T EXPARTE APPEAL TERMINATED Loading...
May 9, 2023 AAUA E NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED Loading...
May 8, 2023 CNTA O APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Loading...
May 8, 2023 IUAA P USE AMENDMENT ACCEPTED Loading...
May 8, 2023 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
May 8, 2023 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
May 8, 2023 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
May 5, 2023 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
May 6, 2023 AUPC I AMENDMENT TO USE PROCESSING COMPLETE Loading...
May 6, 2023 IUAF S USE AMENDMENT FILED Loading...
May 5, 2023 EAAU I TEAS AMENDMENT OF USE RECEIVED Loading...
Nov 8, 2022 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Nov 8, 2022 GNFR O FINAL REFUSAL E-MAILED Loading...
Nov 8, 2022 CNFR R FINAL REFUSAL WRITTEN Loading...
Oct 27, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 26, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 26, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 8, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 8, 2022 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jun 8, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 16, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 16, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 16, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 18, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 18, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 18, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 18, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 26, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical research and development; Pharmaceutical products development; Pharmaceutical drug development services; consulting services in the field of pharmaceutical research and development and medical device and diagnostic research and development
First Use Anywhere: Feb 22, 2022
First Use in Commerce: Feb 22, 2022

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CONSULTING"